A Novel Semi-autonomous Surgeon-in-the-loop in situ Robotic Bioprinting System for Functional and Cosmetic Restoration of Volumetric Muscle Loss Injuries
Full Description
Summary/Abstract:
Our long-goal is to develop an unprecedented semi-autonomous surgeon-in-the-loop surgical robotic
system and complementary computer-assisted algorithms to enable an intuitive in situ robotic
bioprinting of human tissues and organs. More specifically, using this extrusion-based bioprinting system, a
surgeon can (i) first utilize a high-resolution three-dimensional (3D) point cloud camera to plan an arbitrary spatial
printing geometry on the target anatomical surface, (ii) co-operate with a robotic system to manipulate a custom-
designed bioprinting instrument to precisely follow the planned printing geometry, and (iii) perform an intuitive
and precise deposition of engineered bioinks to make tissue constructs on the target anatomical surface, while
(iv) directly control and monitor the printing process to ensure the safety and success of the procedure. The
focus of this proposal is simultaneous functional and cosmetic restoration of large volumetric muscle
loss (VML) injuries by utilizing a novel engineered bioink- developed by our collaborators at the Terasaki
Institute of Biomedical Innovation, a complementary robotic bioprinting system, and intuitive computer-
assisted algorithms.
Severe musculoskeletal injuries can lead to VML, where extensive musculoskeletal damage and tissue loss
result in permanent loss of function. In small-scale injuries or strains, muscle is capable of endogenous
regeneration and complete functional restoration. However, this ability is abated in VML, where the native
biophysical and biochemical signaling cues are no longer present to facilitate tissue regeneration. Current state-
of-the-art in vitro tissue engineering VML treatment procedures suffer from various issues including (i) prolonged
culturing period in bioreactors demanding functionality enhancement prior to implantation in the body; (ii)
adhesion failure of in vitro 3D printed hydrogel scaffolds to the remnant muscle, whether injected, sutured, or
placed into the wound; and (iii) inability to be printed precisely in irregular curved 3D surfaces of large VML
injuries.
It is our central hypothesis that the proposed semi-autonomous robotic bioprinting system can collectively
address the mentioned limitations of the current state-of-the-art solutions by (i) reducing complexity, surgical
time, and complications associated with current VML treatments, (ii) immediately delivering and in situ printing
of appropriate bioinks to the target anatomy and utilizing the human body as a natural bioreactor to induce tissue
maturation and function, and (iii) providing real-time feedback on the 3D bioprinted constructs as well as the
surgeon’s and patient’s motions to ensure precision of the bioprinting procedure for simultaneous functional and
cosmetic restoration of the injured muscle. The proposed project is multidisciplinary and bridges the current gap
between the robotic surgery, tissue engineering, and bioprinting fields. The contribution is significant, high
impact, and innovative and can revolutionize the current clinical paradigm.
Grant Number: 4DP2AR082471-02
NIH Institute/Center: NIH
Principal Investigator: Farshid Alambeigi
Sign up free to get the apply link, save to pipeline, and set email alerts.
Sign up free →Agency Plan
7-day free trialUnlock procurement & grants
Upgrade to access active tenders from World Bank, UNDP, ADB and more — with email alerts and pipeline tracking.
$29.99 / month
- 🔔Email alerts for new matching tenders
- 🗂️Track tenders in your pipeline
- 💰Filter by contract value
- 📥Export results to CSV
- 📌Save searches with one click